Gemcitabine and Oxaliplatin for Lung Cancer
Author Information
Author(s): Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti G V, Crinò L
Primary Institution: Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
Hypothesis
Is gemcitabine plus oxaliplatin an effective first-line chemotherapy for advanced non-small-cell lung cancer?
Conclusion
Gemcitabine-oxaliplatin chemotherapy is active and well tolerated in patients with advanced non-small-cell lung cancer.
Supporting Evidence
- One complete response and 14 partial responses were observed.
- The median duration of response was 5.9 months.
- Median time to progressive disease was 2.7 months.
- Median overall survival was 7.3 months.
- Main grade 3–4 toxicities included neutropenia and thrombocytopenia.
Takeaway
This study tested a new cancer treatment for lung cancer and found that it works pretty well and is not too hard on patients.
Methodology
Patients received gemcitabine and oxaliplatin in a specific schedule and were monitored for responses and side effects.
Potential Biases
Potential bias due to the study being conducted in a limited number of centers.
Limitations
The study was limited to chemonaive patients and had a relatively short follow-up period.
Participant Demographics
The majority of participants were male (71.7%) with a median age of 61 years.
Statistical Information
P-Value
0.025
Confidence Interval
95% CI, 14.7–37.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website